Nasal Swabs for COVID-19 Enter Clinical Trials
Low-cost swabs can be manufactured quickly to address international shortage
Low-cost swabs can be manufactured quickly to address international shortage
This article is part of Harvard Medical School’s continuing coverage of medicine, biomedical research, medical education and policy related to the SARS-CoV-2 pandemic and the disease COVID-19.
Researchers at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering at Harvard University, in collaboration with health care, research and industrial partners, have designed a new, fully injection-molded nasopharyngeal swab that can be manufactured quickly and inexpensively at high volume to help address the nationwide and international shortage of swabs for COVID-19 testing and research.
The swabs are moving into human trials at SUNY Downstate Health Sciences University and University Hospital of Brooklyn and Translational Genomics Research Institute (TGen), an affiliate of City of Hope, a comprehensive cancer center, which should be completed by the end of next week, and they are in preclinical evaluation at six additional hospitals.
Data from the two trials will be used to inform larger trials that include people with COVID-19, and California-based medical device manufacturer Innovative Product Brands (IPB) has been working around the clock to ramp up production of the new swabs to reach 200,000 per day by May 15.
“Experts have recently estimated that the United States needs to more than triple the number of daily COVID-19 tests in order for the country to be safely reopened by mid-May, but the current swabs are complicated to make, and producers just don’t have the ability to increase production to that level in such a short period of time,” said Richard Novak, senior staff engineer at the Wyss Institute, who has been leading the multi-institutional effort to develop a fully injection-molded swab and working with Wyss Founding Director Donald Ingber.
The project began just over a month ago when clinician-researchers at Beth Israel Deaconess Medical Center reached out to Ingber asking for help to solve the hospital’s swab shortage as the COVID-19 pandemic was growing.
Ingber, Novak and a team of Wyss researchers joined the multidisciplinary effort, quickly realizing that not only could they design a swab replacement but the Wyss’s unique position at the intersection of academia and industry meant that it could bring together clinicians who needed swabs, researchers who were developing them and manufacturers who could rapidly produce them at low cost, streamlining the process to get the swabs into the hands of doctors and nurses as quickly as possible.
“The Wyss Institute site on the Longwood campus is physically connected to Beth Israel Deaconess Medical Center, so it makes sense that they would think of the Wyss Institute as an innovation partner with the capability to solve this type of open-ended problem,” said Ingber, the Judah Folkman Professor of Vascular Biology at HMS and Boston Children’s Hospital and professor of bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.
“We were in the midst of figuring out how to shift our staff to work remotely while also starting new COVID-19-related research efforts at the Institute, but the shortage of swabs is such a pressing problem that the decision to help solve it was a no-brainer.”
Designing and delivering a better swab
The nasopharyngeal swabs that have been used in hospitals for more than 50 years consist of two pieces: an injection-molded plastic handle and an absorptive tip made of a soft material such as cotton, polyester or flocked nylon. Each swab is manufactured in a multi-step process, then assembled, sterilized and packaged, all of which requires significant time and expense. As part of the overall effort to create a more streamlined alternative, other teams have leveraged 3D printing to meet this challenge, which has led to some useful short-term solutions. However, 3D printing is costly and can only be done at scale by a limited number of suppliers. The Wyss team set out to create a new design that could be manufactured using injection molding rather than 3D printing because injection molding is faster, less expensive and is routinely used by a broad range of experienced medical device manufacturers worldwide.
“We’ve essentially had to build a medical device company from scratch because we’re trying to create a new product, demonstrate that it works and ship it to customers who need it quickly, and to do that, you need to figure out production, manufacturing, packaging, quality control, clinical trials, etc.,” said Novak. In addition to Novak and Ingber, the Wyss team includes members with diverse skills to address different facets of the project, including Dave Perry, Ramsés Martínez, Isabel Chico-Calero, Adama Sesay, Pawan Jolly and Jenny Tam.
In mid-March, Ramy Arnaout, HMS assistant professor of pathology, and James Kirby, HMS associate professor of pathology, who lead the Clinical Microbiology Laboratory at Beth Israel Deaconess, began collaborating with the Wyss team to develop and test new swab designs that they 3D printed and showed each other via video calls and email, as social distancing measures prevented them from physically working in the same space. Over repeated trials, they eventually settled on a design with a flexible, honey-dipper-like tip that could be injection-molded. The Wyss team has sent prototype injection-molded swabs produced by Proto Labs to eight hospitals and health centers for preclinical testing, in which clinicians are evaluating the swabs’ performance on a variety of fronts, including their comfort, ease of use and ability to collect a large enough sample with detectable amounts of viral RNA.
This week, the swabs are being tested in human subjects who will receive a normal swab in one nostril and a prototype of the Wyss-designed swab in the other. If the new swabs can collect a sample that contains detectable genetic information while being as easy-to-use and comfortable as the existing swabs, IPB will ramp up production of the final injection-molded design, which will be used in future clinical trials and, the team hopes, become widely adopted by the medical community in testing people for COVID-19.
“The speed with which all this is happening is incredible—it is always a challenge to efficiently design a new product even within a standard time frame, and the pandemic has brought challenges that need to be resolved in weeks, even days, which has reminded us how well we can adapt to unexpected situations,” said Martínez, a research assistant who has been working on the design and iteration of the Wyss’ prototype swabs. “Besides addressing the immediate need for swabs, we think that this new design can have sustained use beyond the pandemic because its manufacturing process is cheaper and more streamlined, making it viable in economies outside the United States and hopefully preventing such a shortage from happening in the future.”
From the beginning of the project, the team has been committed to ensuring that their swabs are accessible to hospitals and research facilities around the country to expedite testing. Along with Beth Israel Deaconess, they are part of the Mass General Brigham Center for COVID Innovation that includes members from the majority of hospitals in the Greater Boston area. The center’s Swab Working Group meets regularly via videoconference to update each other on their progress and needs and has made their designs and prototypes freely available. The group also facilitates talks with manufacturing partners to coordinate the production, packaging and delivery of the swabs to hospitals and testing centers, including local companies in Massachusetts and New Hampshire.
“I’ve been really impressed by how collaboratively all these hospitals and companies are working with each other—it shows that the people involved are genuinely invested in developing solutions to save lives during this crisis, in any way they can,” said Perry, a staff engineer at the Wyss who is working on packaging and sterilization solutions for the swabs.
Reaching out and making connections across miles and time zones is what has allowed this week’s trials to take place at SUNY Downstate, TGen’s Pathogen and Microbiome Division, and TGen North. TGen North Clinical Laboratory is testing the new Wyss swabs side-by-side against existing swabs on volunteers from its research labs and is processing COVID-19 tests for several counties and tribal nations in northern Arizona.
“We’ve noticed that the biggest bottleneck in clinicians sending us samples to test is that the swabs they use are in short supply and are back-ordered at all the major manufacturers,” said Timothy McDaniel, the senior vice president of emerging opportunities at TGen. “Having additional manufacturers with the ability to produce swabs on a massive scale will be a huge benefit to medical groups around the country, and we are proud to be helping evaluate the Wyss swabs to further that effort.”
At SUNY Downstate, the swabs are being used alongside existing swabs to collect samples from health care workers in the emergency, intensive care and inpatient departments as part of a small trial to determine if people who are infected with the coronavirus but aren’t showing symptoms can still transmit the virus to others. The university’s Department of Pathology is also working with the Wyss on plans for a larger clinical trial to evaluate the swabs’ performance based on data from the ongoing trial.
“One of the silver linings of this pandemic is that it has really galvanized institutions to reach out to each other and work on solving shared problems together,” said Noriyuki Murakami, a clinical assistant professor in SUNY Downstate’s Department of Medicine and an academic hospitalist overseeing residents at the University Hospital of Brooklyn. “This is the first time we’ve collaborated with the Wyss Institute, and it’s been a great development for SUNY Downstate — we hope this trend continues with other institutions as well.”
“The solution to this crisis will come from the responses of scientists, engineers and clinicians working individually and collaboratively around the world,” Ingber added. “We at the Wyss Institute are proud to be part of the solution; this is precisely why the Institute was created in the first place.”
Adapted from a Wyss news release.